Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study hypothesis is appropriate clinician-patient communication that provides explanations of the reasons for psychoactive drug prescriptions based on the generation of FD symptoms and the drugs' effects might improve compliance with psychoactive agent regimens among FD patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Treatments: Antidepressive Agents; Flupenthixol; Flupenthixol decanoate; Omeprazole

Criteria

Inclusion Criteria:

• met the ROME III criteria for FD;

• education level no lower than high school;

• Hospital Anxiety and Depression Scale (HADS) score > 8 respectively;

• absence of abnormalities in physical examination, laboratory tests (including a routine blood test, blood glucose, and liver function examination), abdominal ultrasonography and upper GI endoscopy within 6 months;

• absence of H. pylori infection

Exclusion Criteria:

• known allergy to omeprazole, flupenthixol or melitracen;

• any evidence of organic digestive diseases;

• reflux-related symptoms only (e.g., retrosternal pain, burning and regurgitation) or predominantly reflux-related symptoms;

• severe psychological symptoms that affected life and work;

• pregnancy or breastfeeding;

• recent myocardial infarction or cardiac arrhythmias;

• previous gastric surgery;

• use of PPIs, psychoactive drugs or other drugs that might affect gastric function within 6 months